I think this response in the market is way overdone.
Notwithstanding though, I think MSB needs to get some new people involved in the design and implementation of the programs and equally importantly, in how those plans are laid out and reported to the market.
I still think we have great tech but not unusually, geeks aren't much good at explaining what they are doing.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-434
-
- There are more pages in this discussion • 642 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |